Acer Therapeutics Inc. (ACER) News
Filter ACER News Items
ACER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACER News Highlights
- For ACER, its 30 day story count is now at 4.
- Over the past 26 days, the trend for ACER's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE, APTX and BIO are the most mentioned tickers in articles about ACER.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical OfficerIndustry veteran with over 20 years of drug development experience to oversee advancement of Acer’s product pipeline Adrian Quartel, MD, FFPM Dr. Quartel joins Acer Therapeutics as Chief Medical Officer NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the appo |
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year. |
Acer Therapeutics to Participate in 2022 BIO CEO & Investor ConferenceNEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually participate in the BIO CEO & Investor Conference on February 14-17, 2022. Format:On-demand recorded corporate presentation and one-on-one virtual meetingsDates:Februar |
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI ConferencesData to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDsNEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced the acceptance of four ACER-001 abstracts for poster presentations at the upcoming Society for Inherited Metabolic Disorders (SIMD) Annual M |
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year. |
We're Interested To See How Acer Therapeutics (NASDAQ:ACER) Uses Its Cash Hoard To GrowJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Acer Therapeutics to Participate in January 2022 Virtual Investor ConferencesNEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference. Conference:11th Annual LifeSci Part |
Comparing Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI)Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and [] |
Acer Therapeutics wins FDA nod for hot flashes trialNo summary available. |
Acer Therapeutics (NASDAQ:ACER) Stock Rating Upgraded by Zacks Investment ResearchAcer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of [] |